31.9 USD
-1.13 (-3.42%)
At close: Feb 4, 2026
32.04 USD
+0.14 (+0.44%)
After Hours: 2/4/2026, 8:24:39 PM
We assign a fundamental rating of 7 out of 10 to GMAB. GMAB was compared to 524 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make GMAB a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
- GMAB had positive earnings in the past year.
- In the past year GMAB had a positive cash flow from operations.
- Each year in the past 5 years GMAB has been profitable.
- Each year in the past 5 years GMAB had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 21.10%, GMAB belongs to the best of the industry, outperforming 97.33% of the companies in the same industry.
- GMAB has a Return On Equity of 25.76%. This is amongst the best in the industry. GMAB outperforms 97.14% of its industry peers.
- GMAB has a better Return On Invested Capital (17.11%) than 96.76% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for GMAB is below the industry average of 18.09%.
- The last Return On Invested Capital (17.11%) for GMAB is above the 3 year average (15.20%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
- GMAB has a Profit Margin of 41.35%. This is amongst the best in the industry. GMAB outperforms 97.33% of its industry peers.
- In the last couple of years the Profit Margin of GMAB has declined.
- GMAB has a Operating Margin of 36.85%. This is amongst the best in the industry. GMAB outperforms 97.90% of its industry peers.
- In the last couple of years the Operating Margin of GMAB has declined.
- Looking at the Gross Margin, with a value of 94.27%, GMAB belongs to the top of the industry, outperforming 94.85% of the companies in the same industry.
- In the last couple of years the Gross Margin of GMAB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
- The number of shares outstanding for GMAB has been reduced compared to 1 year ago.
- Compared to 5 years ago, GMAB has less shares outstanding
- Compared to 1 year ago, GMAB has a worse debt to assets ratio.
2.2 Solvency
- GMAB has an Altman-Z score of 12.18. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
- GMAB's Altman-Z score of 12.18 is amongst the best of the industry. GMAB outperforms 83.97% of its industry peers.
- The Debt to FCF ratio of GMAB is 0.12, which is an excellent value as it means it would take GMAB, only 0.12 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of GMAB (0.12) is better than 95.80% of its industry peers.
- GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
- GMAB has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: GMAB outperforms 43.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 12.18 |
ROIC/WACC2.34
WACC7.32%
2.3 Liquidity
- GMAB has a Current Ratio of 6.03. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
- GMAB has a better Current ratio (6.03) than 62.79% of its industry peers.
- GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 6.01, GMAB is doing good in the industry, outperforming 63.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 125.90% over the past year.
- The Earnings Per Share has been growing by 28.38% on average over the past years. This is a very strong growth
- The Revenue has grown by 24.66% in the past year. This is a very strong growth!
- The Revenue has been growing by 31.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
- The Earnings Per Share is expected to grow by 9.30% on average over the next years. This is quite good.
- The Revenue is expected to grow by 13.38% on average over the next years. This is quite good.
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y9.3%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- GMAB is valuated correctly with a Price/Earnings ratio of 13.52.
- 96.76% of the companies in the same industry are more expensive than GMAB, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 28.25. GMAB is valued rather cheaply when compared to this.
- Based on the Price/Forward Earnings ratio of 18.74, the valuation of GMAB can be described as rather expensive.
- Based on the Price/Forward Earnings ratio, GMAB is valued cheaply inside the industry as 93.70% of the companies are valued more expensively.
- GMAB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.50.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.52 | ||
| Fwd PE | 18.74 |
4.2 Price Multiples
- GMAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GMAB is cheaper than 96.95% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, GMAB is valued cheaper than 96.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.33 | ||
| EV/EBITDA | 11.13 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GMAB does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of GMAB may justify a higher PE ratio.
PEG (NY)2.1
PEG (5Y)0.48
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
5. Dividend
5.1 Amount
- GMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
31.9
-1.13 (-3.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.65B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts71.85
Price Target28.4 (-10.97%)
Short Float %1.68%
Short Ratio6.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)300.02%
Revenue beat(12)10
Avg Revenue beat(12)350.69%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.44%
EPS NQ rev (3m)0.39%
EPS NY rev (1m)3.51%
EPS NY rev (3m)11.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.52 | ||
| Fwd PE | 18.74 | ||
| P/S | 5.48 | ||
| P/FCF | 16.33 | ||
| P/OCF | 15.42 | ||
| P/B | 3.42 | ||
| P/tB | 5.39 | ||
| EV/EBITDA | 11.13 |
EPS(TTM)2.36
EY7.4%
EPS(NY)1.7
Fwd EY5.34%
FCF(TTM)1.95
FCFY6.13%
OCF(TTM)2.07
OCFY6.49%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)2.1
PEG (5Y)0.48
Graham Number22.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 12.18 |
F-Score7
WACC7.32%
ROIC/WACC2.34
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y9.3%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 7 / 10 to GMAB.
What is the valuation status for GMAB stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for GMAB stock?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 13.52 and the Price/Book (PB) ratio is 3.42.
Can you provide the financial health for GMAB stock?
The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.